Want to see ARCT full AI Analyst Report?
ARCT Stock Chart & Stats
$8.85
-$1.70(-8.19%)
At close: 4:00 PM EST
$8.85
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.50 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)829.62K
Market Cap
$163.72M
Enterprise Value$32.02
Total Cash (Recent Filing)$211.38M
Total Debt (Recent Filing)$23.99M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Aug 06, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding28,423,069
10 Day Avg. Volume934,920
30 Day Avg. Volume829,622
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.78
Price to Sales (P/S)2.50
P/FCF Ratio-2.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside125.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.03
Revenue Forecast (FY)$15.28M
Bulls Say, Bears Say
Bulls Say
Balance Sheet ResilienceLow leverage and substantial equity give Arcturus structural financial flexibility to fund clinical programs without heavy near-term debt. This supports runway extension, limits interest burden, and preserves optionality for partnering or milestone-based financing across the next 2–6 months.
Multi-year Cash RunwayA stated cash runway into mid‑2028 materially reduces near-term financing pressure and supports completion of pivotal development steps. Sustained liquidity allows prioritized R&D spend, enrollment and regulatory interactions without immediate dilutive financings over the coming 2–6 months.
Clinical And Regulatory MomentumDemonstrating repeat inhaled dosing tolerability validates core LNP delivery chemistry and reduces technical risk for respiratory mRNA assets. Coupled with FDA clarity for ARCT-810, this advances regulatory de‑risking and makes later-stage partnering or pivotal planning more viable.
Bears Say
Sharply Falling RevenueA substantial and persistent revenue decline erodes operating leverage and strains the company’s ability to fund programs internally. Reduced partner income increases reliance on cash reserves or external financing, lowering visibility on sustainable funding beyond milestone events.
Negative Cash GenerationConsistent negative operating and free cash flow means the business depends on existing liquidity or external capital to progress trials. Continued cash burn can compress runway if milestones slip, forcing potentially dilutive financings or partnership concessions within the medium term.
Small Open‑label CF Study & Modality RiskA small, open‑label trial limits interpretability and increases regulatory uncertainty for a new inhaled mRNA modality. Coupled with peer trial discontinuations, this raises execution and approval risk, potentially requiring larger follow‑on studies or tougher endpoints before pivotal acceptance.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.50 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $163.72M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 8 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.01 by $0.06.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -1.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,423,069 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.01. Following the earnings report the stock price went up 3.596%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (125.99% Upside)
$20.00 (125.99% Upside)
Hedge Fund Trend
Increased
By 91.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.03%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage biotechnology company focused on developing RNA-based medicines. The company’s programs primarily use messenger RNA (mRNA) and self-amplifying mRNA (sa-mRNA) delivered via its lipid nanoparticle (LNP) delivery technology, with a pipeline spanning infectious disease vaccines and therapeutic candidates for other diseases. Arcturus also develops and licenses enabling technologies related to RNA therapeutics and delivery.
ARCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful clinical and regulatory progress — notably initiation of a 12‑week ARCT‑032 Phase II with tolerable repeat inhaled dosing and FDA clarity on ARCT‑810 pediatric path — supported by a strengthened leadership team and a cash runway through mid‑2028. Offsetting these positives were a material year‑over‑year revenue decline ($27.3M), a quarter‑over‑quarter cash decrease (~$19.4M, 8.3%), program‑specific manufacturing cost increases, and uncertainties tied to a small open‑label CF study and broader modality risk. On balance, the advancement of key programs and regulatory alignment outweigh the financial and operational headwinds in the near term.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$20.00
▲(125.99% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
8.04% Insiders
23.74% Mutual Funds
2.62% Other Institutional Investors
43.97% Public Companies and
Individual Investors